Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

On February 5, 2025, the first working day of the Year of the Snake, Guangdong held a provincial high-quality development conference in Guangzhou to conduct in-depth exchanges and discussions on ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching US$ 0.81 Billion in ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, reaching US$ 13.28 ...

The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

but asset prices when measured as a multiple of earnings are high, she added. "We're not planning any transformational deals in pharma," Garijo said, adding that Merck is looking at bolt-on ...